Oberg K
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Chemotherapy. 2001;47 Suppl 2:40-53. doi: 10.1159/000049160.
The diagnosis and treatment of neuroendocrine tumors have been significantly improved during the last decades. Localization and staging of the disease by somatostatin receptor scintigraphy (Octreoscan) are now the 'gold standard' for the management of these tumors. Treatment with somatostatin analogs has improved quality of life and possibly also survival for patients with neuroendocrine tumors. New long-acting formulations of the somatostatin analogs are as effective as the old regular formulations but will further improve quality of life for the patients. Tumor-targeted therapy with (111)In and (90)Y coupled to somatostatin analogs show promising results but await further studies.
在过去几十年中，神经内分泌肿瘤的诊断和治疗有了显著改善。通过生长抑素受体闪烁显像（奥曲肽扫描）对疾病进行定位和分期，如今已成为这些肿瘤管理的“金标准”。生长抑素类似物治疗改善了神经内分泌肿瘤患者的生活质量，并且可能也延长了生存期。生长抑素类似物的新型长效制剂与旧的常规制剂效果相同，但将进一步改善患者的生活质量。与生长抑素类似物偶联的（111）铟和（90）钇的肿瘤靶向治疗显示出有前景的结果，但仍有待进一步研究。
